Canada Markets closed

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.5200-0.2900 (-7.61%)
At close: 04:00PM EST
3.5200 0.00 (0.00%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.8100
Open3.6400
Bid3.5000 x 800
Ask3.5900 x 900
Day's Range3.4800 - 3.6700
52 Week Range2.2300 - 6.3800
Volume258,890
Avg. Volume2,768,975
Market Cap155.536M
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-1.2570
Earnings DateMar. 23, 2022 - Mar. 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.56
  • GlobeNewswire

    InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor

    Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR. “Inhibition of the C5a/C5aR axis provides strong anti-inflammatory effects in a vari

  • GlobeNewswire

    InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events

    Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at sev

  • GlobeNewswire

    InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)

    Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of careUse of vilobelimab instead of glucocorticoids led to a substantially lower observed glucocorticoid toxicityVilobelimab demonstrated a good safety and tolerability profile; vilobelimab only treatment arm had lowest number of reported treatment emergent adverse events JENA, Germany, Nov. 15, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V.